Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
DUBLIN, Ireland , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
-Relaunch of Xenleta ® and Sivextro ® commenced in late September-   - Type A Meeting with FDA for Contepo™ held on October 30 th - -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
View HTML
Toggle Summary Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
DUBLIN, Ireland , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial
View HTML
Toggle Summary Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes -- -- Pooled analysis of data by age group from pivotal LEAP 1 and LEAP 2 Phase 3
View HTML
Toggle Summary Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland , Sept.
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
View HTML
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
-SIVEXTRO ® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA ® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
DUBLIN, Ireland , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
DUBLIN, Ireland , July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com